Study of TB006 in Outpatient Patients With Mild to Moderate COVID-19
Status:
Withdrawn
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
TB006, a monoclonal antibody, is an anti-inflammatory and anti-fibrotic agent that reduces
the severity of underlying diseases in COVID-19 patients. The primary objective of TB006
treatment is to decrease the potential acute severe deterioration in outpatient COVID-19
patients with underlying diseases, such as diabetes, hypertension, and cancer. TB006 has been
developed to treat the ambulatory patients with diagnosed mild to moderate COVID-19 who are
considered at low risk for severe disease or hospitalization.